⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NUVB News
Nuvation Bio Inc.
Nuvation Bio to Participate in Upcoming Investor Conferences
prnewswire.com
NUVB
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
prnewswire.com
NUVB
Form 8-K
sec.gov
NUVB
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
prnewswire.com
NUVB
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
prnewswire.com
NUVB
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
prnewswire.com
NUVB
Form 8-K
sec.gov
NUVB
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
prnewswire.com
NUVB
Form 8-K
sec.gov
NUVB
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
prnewswire.com
NUVB